- Home
- MCHB vs VKTX Comparison
MCHB vs VKTX Comparison
Compare MCHB & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCHB | VKTX |
|---|---|---|
| Founded | 1905 | 2012 |
| Country | United States | United States |
| Employees | 1890 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MCHB | VKTX |
|---|---|---|
| Price | $15.68 | $34.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.75 | ★ $95.86 |
| AVG Volume (30 Days) | 575.4K | ★ 2.4M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $22.96 |
| 52 Week High | $16.68 | $43.15 |
Technical Indicators
Market Signals| Indicator | MCHB | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 44.70 |
| Support Level | $15.41 | $34.03 |
| Resistance Level | $16.03 | $36.77 |
| Average True Range (ATR) | 0.44 | 2.05 |
| MACD | -0.09 | -0.66 |
| Stochastic Oscillator | 18.16 | 3.75 |
Price Performance
Historical ComparisonAbout MCHB Mechanics Bancorp
Mechanics Bancorp is the financial holding company of Mechanics Bank, a full-service bank with branches across California, Oregon, Washington and Hawaii. It offers a various products and services in consumer and business banking, commercial lending, cash management services, private banking, and comprehensive wealth management and trust services.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.